Prevalence of Colorectal Cancer Screening in a Large Medical Organization
Overview
Oncology
Public Health
Affiliations
The primary objective of this study was to determine the prevalence of colorectal cancer (CRC) screening among eligible patients in a large medical practice. A secondary objective was to compare CRC screening rates obtained from medical records with physician self-reported CRC screening recommendation. We conducted a retrospective record review of 214 patients ages > or = 50 years of a large multispecialty medical organization in Houston, Texas, for receipt of fecal occult blood test (FOBT), flexible sigmoidoscopy (SIG), and/or colonoscopy (COL). We estimated prevalence using two definitions: (a) FOBT in past year or SIG in past 5 years or COL in past 10 years; and (b) FOBT in past year and SIG in past 5 years or COL in past 10 years. Age, gender, race/ethnicity, family history, number of chronic conditions, and index visit were independent variables. Contingency table and logistic regression analysis were used to test for associations between outcomes and independent variables. Our study population was 48% male with a mean age of 63 years (range: 53-84 years). One-quarter of the records showed FOBT by 3-day kit (51 of 214) and 27% by digital rectal exam (57 of 214). SIG was recorded in 32% of records. Half (54%) of the records had documentation of CRC screening according to definition no. 1 and 19% according to definition no. 2. Screening rates from medical record review were lower than those derived from physician self-report. Our findings underscore the need for interventions to improve CRC screening in primary care settings.
The significance of elevated tumor markers among patients with interstitial lung diseases.
Kwon B, Kim E, Lim S, Song M, Kim Y, Kim H Sci Rep. 2022; 12(1):16702.
PMID: 36202924 PMC: 9537420. DOI: 10.1038/s41598-022-20683-w.
Kozlowska E, Szewczyk M Contemp Oncol (Pozn). 2013; 16(6):557-62.
PMID: 23788944 PMC: 3687468. DOI: 10.5114/wo.2012.32490.
Knowledge of symptoms and diagnostic possibilities of cancer diseases.
Kozlowska E, Szewczyk M, Banaszkiewicz Z, Jawien A, Cierzniakowska K, Jarmocik P Arch Med Sci. 2012; 7(2):304-9.
PMID: 22291771 PMC: 3258706. DOI: 10.5114/aoms.2011.22082.
Curry W, Lengerich E, Kluhsman B, Graybill M, Liao J, Schaefer E BMC Health Serv Res. 2011; 11:112.
PMID: 21600059 PMC: 3128846. DOI: 10.1186/1472-6963-11-112.
Process evaluation of recruitment for a cancer screening trial in primary care.
James A, Daley C, Engelman K, Greiner K, Ellerbeck E Health Promot Pract. 2011; 12(5):696-703.
PMID: 21471439 PMC: 3319739. DOI: 10.1177/1524839910366402.